Caren Begun for Penn Medicine News: “‘Lighting up cancer, which helps to identify lesions that may be difficult to find—especially in the presence of scar tissue or other organ damage—enables more complete identification and surgical removal of cancer that could have otherwise been missed,’ said Janos L. Tanyi, MD, PhD, an Associate Professor of Obstetrics and Gynecology in the Perelman School of Medicine at Penn and Principal Investigator at Penn’s clinical trial site for Phase 2 and Phase 3 studies. ‘This FDA approval offers more precise surgical intervention for patients with ovarian cancer who face a high risk of recurrence after their initial treatment.'”
